| 1 |
Pharmaceutical industry contribution to research is essential but full transparency and guidelines are required |
|
| | Amir Lass | | | Human Reproduction. 2017; 32(10): 2147 | | | [Pubmed] [Google Scholar] [DOI] | | | 2 |
Opportunities and Challenges for Drug Development: Public–Private Partnerships, Adaptive Designs and Big Data |
|
| | Oktay Yildirim,Matthias Gottwald,Peter Schüler,Martin C. Michel | | | Frontiers in Pharmacology. 2016; 7 | | | [Pubmed] [Google Scholar] [DOI] | | | 3 |
Fellow-Initiated Clinical Trials |
|
| | Yan Liu,Xuming Dai | | | Journal of the American College of Cardiology. 2015; 66(3): 324 | | | [Pubmed] [Google Scholar] [DOI] | | | 4 |
Extension of the primary care research object model (PCROM) as clinical research information model (CRIM) for the “learning healthcare system” |
|
| | Wolfgang Kuchinke,Töresin Karakoyun,Christian Ohmann,Theodoros N Arvanitis,Adel Taweel,Brendan C Delaney,Stuart M Speedie | | | BMC Medical Informatics and Decision Making. 2014; 14(1) | | | [Pubmed] [Google Scholar] [DOI] | |
|
